LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 140

Search options

  1. Article: Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.

    Faqihi, Fahad / Alharthy, Abdulrahman / Karakitsos, Dimitrios

    Journal of the Formosan Medical Association = Taiwan yi zhi

    2020  Volume 119, Issue 12, Page(s) 1888–1889

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/therapy ; Cytokine Release Syndrome ; Cytokines ; Humans ; Pandemics ; Plasma Exchange ; Pneumonia, Viral ; SARS-CoV-2
    Chemical Substances Cytokines
    Keywords covid19
    Language English
    Publishing date 2020-07-13
    Publishing country Singapore
    Document type Letter ; Comment
    ZDB-ID 2096659-3
    ISSN 1876-0821 ; 0929-6646
    ISSN (online) 1876-0821
    ISSN 0929-6646
    DOI 10.1016/j.jfma.2020.07.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Effect of Tocilizumab on "Ventilator Free Days" Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis.

    Mady, Ahmed F / Abdulrahman, Basheer / Mumtaz, Shahzad A / Al-Odat, Mohammed A / Kuhail, Ahmed / Altoraifi, Rehab / Alshae, Rayan / Alharthy, Abdulrahman M / Karakitsos, Dimitrios / Aletreby, Waleed Th

    Romanian journal of anaesthesia and intensive care

    2023  Volume 29, Issue 1, Page(s) 1–7

    Abstract: Background: SARS-CoV-2 infection demonstrates a wide range of severity. More severe cases demonstrate a cytokine storm with elevated serum interleukin-6, hence IL-6 receptor antibody tocilizumab was tried for the management of severe cases.: Aims: ... ...

    Abstract Background: SARS-CoV-2 infection demonstrates a wide range of severity. More severe cases demonstrate a cytokine storm with elevated serum interleukin-6, hence IL-6 receptor antibody tocilizumab was tried for the management of severe cases.
    Aims: Effect of tocilizumab on ventilator-free days among critically ill SARS-CoV-2 patients.
    Method: Retrospective propensity score matching study, comparing mechanically ventilated patients who received tocilizumab to a control group.
    Results: 29 patients in the intervention group were compared to 29 controls. Matched groups were similar. Ventilator-free days were more numerous in the intervention group (SHR 2.7, 95% CI: 1.2 - 6.3; p = 0.02), ICU mortality rate was not different (37.9% versus 62%, p = 0.1), actual ventilator-free periods were significantly longer in tocilizumab group (mean difference 4.7 days; p = 0.02). Sensitivity analysis showed a significantly lower hazard ratio of death in tocilizumab group (HR 0.49, 95% CI: 0.25 - 0.97; p = 0.04). There was no difference in positive cultures among groups (55.2% in tocilizumab group versus 34.5% in the control; p = 0.1).
    Conclusion: Tocilizumab may improve the composite outcome of ventilator-free days at day 28 among mechanically ventilated SARS-CoV-2 patients; it is associated with significantly longer actual ventilator-free periods, and insignificantly lower mortality and higher superinfection.
    Language English
    Publishing date 2023-01-14
    Publishing country Romania
    Document type Journal Article
    ZDB-ID 2977912-1
    ISSN 2502-0307 ; 2392-7518
    ISSN (online) 2502-0307
    ISSN 2392-7518
    DOI 10.2478/rjaic-2022-0001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: COVID-19 air travel restrictions and vaccine passports: An ongoing debate.

    Memish, Ziad A / Alharthy, Abdulrahman / Alqahtani, Saleh A / Karakitsos, Dimitrios

    Travel medicine and infectious disease

    2021  Volume 42, Page(s) 102049

    MeSH term(s) Air Travel/economics ; Air Travel/legislation & jurisprudence ; COVID-19/economics ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19/transmission ; COVID-19 Vaccines ; Consensus ; Dissent and Disputes ; Economic Factors ; Humans ; SARS-CoV-2 ; Vaccination/legislation & jurisprudence ; World Health Organization
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-04-20
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2170891-5
    ISSN 1873-0442 ; 1477-8939
    ISSN (online) 1873-0442
    ISSN 1477-8939
    DOI 10.1016/j.tmaid.2021.102049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: SARS-CoV-2 Complicated by Sinusitis and Co-Infection with Human Metapneumovirus.

    Alharthy, Abdulrahman / Faqihi, Fahad / Karakitsos, Dimitrios

    Rhode Island medical journal (2013)

    2020  Volume 103, Issue 6, Page(s) 23–24

    Abstract: A previously healthy 25-year-old Asian male was admitted with acute respiratory failure due to COVID-19 pneumonia to our intensive care unit. He received empiric therapy and higher level of respiratory support via a high flow nasal cannula. Notably, ... ...

    Abstract A previously healthy 25-year-old Asian male was admitted with acute respiratory failure due to COVID-19 pneumonia to our intensive care unit. He received empiric therapy and higher level of respiratory support via a high flow nasal cannula. Notably, human metapneumovirus was detected from the nasopharyngeal swab by RT-PCR. Six days post-ICU admission, sinusitis was clinically and sonographically detected. SARS-CoV-2 was detected in the fluid aspirated from the antrum. The patient has made an uneventful recovery. Further studies are required to investigate co-infections with SARS-CoV-2 and other viruses.
    MeSH term(s) Adult ; Betacoronavirus/isolation & purification ; COVID-19 ; Coinfection ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/therapy ; Humans ; Intensive Care Units ; Male ; Metapneumovirus/isolation & purification ; Nasopharynx/virology ; Pandemics ; Paramyxoviridae Infections/complications ; Paramyxoviridae Infections/diagnosis ; Paramyxoviridae Infections/therapy ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/therapy ; SARS-CoV-2 ; Sinusitis/diagnostic imaging
    Keywords covid19
    Language English
    Publishing date 2020-08-03
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 419430-5
    ISSN 2327-2228 ; 0363-7913
    ISSN (online) 2327-2228
    ISSN 0363-7913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome

    Fahad Faqihi / Abdulrahman Alharthy / Dimitrios Karakitsos

    Journal of the Formosan Medical Association, Vol 119, Iss 12, Pp 1888-

    2020  Volume 1889

    Keywords Medicine (General) ; R5-920
    Language English
    Publishing date 2020-12-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: The potential role of extracorporeal cytokine removal with CytoSorb® as an adjuvant therapy in Acute Respiratory Distress Syndrome.

    Tomescu, Dana / Popescu, Mihai / Akil, Ali / Nassiri, Amir Ahmad / Wunderlich-Sperl, Florian / Kogelmann, Klaus / Molnar, Zsolt / Alharthy, Abdulrahman / Karakitsos, Dimitrios

    The International journal of artificial organs

    2023  Volume 46, Issue 12, Page(s) 605–617

    Abstract: Management of acute respiratory distress syndrome (ARDS) represents one of the greatest challenges in intensive care and despite all efforts mortality remains high. One common phenotype of ARDS is that of a secondary injury to a dysregulated inflammatory ...

    Abstract Management of acute respiratory distress syndrome (ARDS) represents one of the greatest challenges in intensive care and despite all efforts mortality remains high. One common phenotype of ARDS is that of a secondary injury to a dysregulated inflammatory host response resulting in increased capillary congestion, interstitial lung edema, atelectasis, pulmonary embolism, muscle wasting, recurring infectious episodes, and multiple organ failure. In cases of hyperinflammation, immunomodulation by extracorporeal cytokine removal such as the CytoSorb hemoadsorption cartridge could conceptually enhance lung recovery during the early course of the disease. The aim of this narrative review is to summarize the currently available data in this field and to provide an overview of pathophysiology and rationale for the use of CytoSorb hemoadsorption in patients with hyperinflammatory ARDS.
    MeSH term(s) Humans ; Cytokines ; Extracorporeal Membrane Oxygenation/methods ; Hemoperfusion/methods ; Multiple Organ Failure ; Respiratory Distress Syndrome/therapy
    Chemical Substances Cytokines
    Language English
    Publishing date 2023-12-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80456-3
    ISSN 1724-6040 ; 0391-3988
    ISSN (online) 1724-6040
    ISSN 0391-3988
    DOI 10.1177/03913988231211740
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Comment on Hu et al: The cytokine storm and COVID-19.

    Faqihi, Fahad / Alharthy, Abdulrahman / Memish, Ziad A / Karakitsos, Dimitrios

    Journal of medical virology

    2020  Volume 93, Issue 2, Page(s) 631–633

    MeSH term(s) COVID-19 ; Cytokine Release Syndrome ; Cytokines ; Humans ; SARS-CoV-2
    Chemical Substances Cytokines
    Keywords covid19
    Language English
    Publishing date 2020-08-21
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26396
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Lung Injury in COVID-19-An Emerging Hypothesis.

    Alharthy, Abdulrahman / Faqihi, Fahad / Memish, Ziad A / Karakitsos, Dimitrios

    ACS chemical neuroscience

    2020  Volume 11, Issue 15, Page(s) 2156–2158

    Abstract: Lung injury with COVID-19 may be due to a complex underlying pathophysiology. Cytokine release syndrome appears to be a catalyst of different inflammatory pathways promoting lung parenchymal injury and thromboembolic phenomena ("dual hit" injury). ... ...

    Abstract Lung injury with COVID-19 may be due to a complex underlying pathophysiology. Cytokine release syndrome appears to be a catalyst of different inflammatory pathways promoting lung parenchymal injury and thromboembolic phenomena ("dual hit" injury). Recently, severe neurological manifestations such as acute disseminated encephalomyelitis, which may be not linked to lung pathology, have been identified in COVID-19, contributing thus further to the versatility of its clinical features.
    MeSH term(s) Animals ; Betacoronavirus/metabolism ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/metabolism ; Coronavirus Infections/physiopathology ; Cytokines/metabolism ; Humans ; Lung Injury/etiology ; Lung Injury/metabolism ; Lung Injury/physiopathology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/physiopathology ; SARS-CoV-2
    Chemical Substances Cytokines
    Keywords covid19
    Language English
    Publishing date 2020-07-24
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1948-7193
    ISSN (online) 1948-7193
    DOI 10.1021/acschemneuro.0c00422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: "Ventilator-free days" composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis.

    Mady, Ahmed F / Abdulrahman, Basheer / Mumtaz, Shahzad A / Al-Odat, Mohammed A / Kuhail, Ahmed / Altoraifi, Rehab / Alshae, Rayan / Alharthy, Abdulrahman M / Aletreby, Waleed Th

    Heart & lung : the journal of critical care

    2022  Volume 56, Page(s) 118–124

    Abstract: Background: SARS-CoV-2 infection demonstrates a wide range of severity, with more severe cases presenting with a cytokine storm with elevated serum interleukin-6; hence, the interleukin-6 receptor antibody tocilizumab was used for the management of ... ...

    Abstract Background: SARS-CoV-2 infection demonstrates a wide range of severity, with more severe cases presenting with a cytokine storm with elevated serum interleukin-6; hence, the interleukin-6 receptor antibody tocilizumab was used for the management of severe cases.
    Objective: To explore the effect of tocilizumab on ventilator-free day composite outcomes among critically ill patients with SARS-CoV-2 infection.
    Methods: This retrospective propensity score-matching study compared mechanically ventilated patients who received tocilizumab to a control group.
    Results: Twenty-nine patients in the intervention group were compared to 29 controls. The matched groups were similar. The ventilator-free days composite outcome was higher in the intervention group (sub-distribution hazard ratio 2.7, 95% confidence interval [CI]: 1.2-6.3; p = 0.02), the mortality rate in the intensive care unit was not different (37.9% vs 62%, p = 0.1), and actual ventilator-free days were significantly longer in the tocilizumab group (mean difference 4.7 days; p = 0.02). Sensitivity analysis showed a significantly lower hazard ratio for death in the tocilizumab group (HR 0.49, 95% CI: 0.25-0.97; p = 0.04). Positive cultures were not significantly different among the groups (55.2% vs 34.5% in the tocilizumab and control groups, respectively; p = 0.1).
    Conclusions: Tocilizumab may improve the composite outcome of ventilator-free days at day 28 among mechanically ventilated patients with SARS-CoV-2 infection. It is associated with significantly longer actual ventilator-free days, insignificantly lower mortality, and higher superinfection.
    MeSH term(s) Humans ; COVID-19 ; SARS-CoV-2 ; Retrospective Studies ; Interleukin-6 ; Receptors, Interleukin-6 ; Risk Assessment ; Treatment Outcome ; Respiration, Artificial ; COVID-19 Drug Treatment
    Chemical Substances tocilizumab (I031V2H011) ; Interleukin-6 ; Receptors, Interleukin-6
    Language English
    Publishing date 2022-06-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193129-5
    ISSN 1527-3288 ; 0147-9563
    ISSN (online) 1527-3288
    ISSN 0147-9563
    DOI 10.1016/j.hrtlng.2022.06.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top